Premium
The brain‐derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia
Author(s) -
Bonaccorso Stefania,
Sodhi Monsheel,
Li Jiang,
Bobo William V,
Chen Yuejin,
Tumuklu Mevhibe,
Theleritis Christos,
Jayathilake Karuna,
Meltzer Herbert Y
Publication year - 2015
Publication title -
bipolar disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.285
H-Index - 129
eISSN - 1399-5618
pISSN - 1398-5647
DOI - 10.1111/bdi.12294
Subject(s) - medicine , schizoaffective disorder , body mass index , endocrinology , insulin resistance , bipolar disorder , risperidone , quetiapine , olanzapine , metabolic syndrome , aripiprazole , schizophrenia (object oriented programming) , glycated hemoglobin , atypical antipsychotic , psychology , antipsychotic , obesity , diabetes mellitus , psychiatry , type 2 diabetes , psychosis , lithium (medication)
Objectives We tested the hypothesis that a common functional variant in brain‐derived neurotrophic factor ( BDNF ), Val66Met, which has been shown to be associated with increased body mass index ( BMI ) in schizophrenia ( SCZ ) and schizoaffective disorder ( SAD ), is also associated with antipsychotic‐induced weight gain in bipolar disorder ( BPD ). Association of Val66Met with other metabolic measures, including high‐ and low‐density cholesterol, triglycerides, total cholesterol, fasting blood glucose, and hemoglobin A1c, was also tested. Methods This was a 12‐month, prospective, randomized trial of two atypical antipsychotic drugs ( APD s) with moderate (risperidone) or high (olanzapine) risk to cause weight gain. Subjects were diagnosed as having BPD (n = 90) and SCZ or SAD (n = 76). Results BMI was significantly greater in all diagnoses for Met66 allele carriers at six months (p = 0.01). Met66 carriers with BPD showed a greater increase in the triglycerides/high‐density ( HDL ) cholesterol ratio (p = 0.01), a key marker for metabolic syndrome related to insulin resistance, and log‐triglycerides (p = 0.04), after three or six months of treatment. Met66 carriers had the greatest increase in log‐triglycerides (p = 0.03) and triglycerides/ HDL cholesterol ratio after three months of treatment with risperidone (p = 0.003), and the highest BMI at six months (p = 0.01). Conclusions The positive association of BNDF Val66Met with high BMI values replicates previous findings in patients with SCZ and indicates the BDNF Val66Met genotype as a potential risk factor for obesity and insulin resistance measures in patients with BPD receiving antipsychotics as well.